FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1786366031> ?p ?o ?g. }

• W1786366031 endingPage "126" @default.
• W1786366031 startingPage "119" @default.
• W1786366031 abstract "PURPOSE This phase II study was designed to evaluate effectiveness and toxicity of a combined chemoradiotherapy program with selective bladder preservation in the management of patients with invasive bladder cancer. PATIENTS AND METHODS Ninety-one eligible patients with invasive bladder cancer stages T2M0 to T4AM0 suitable for radical cystectomy received two courses of methotrexate, cisplatin, and vinblastine (MCV regimen) followed by radiotherapy with 39.6 Gy and concurrent cisplatin. After complete urologic evaluation, operable patients who achieved complete response were selected for bladder preservation and treated with consolidation cisplatin-radiotherapy. RESULTS Of 91 eligible patients, 85 underwent complete urologic evaluation and 68 (75%; 95% confidence interval [CI], 59% to 84%) had documented complete responses. Fourteen operable patients with residual tumor underwent immediate cystectomy. Of 70 patients treated with consolidation cisplatin-radiotherapy, 36 subsequently developed bladder recurrences, 23 of which were invasive. Patients with invasive recurrence (n = 16), extensive noninvasive recurrence (n = 6), or severe treatment complications (n = 1) underwent salvage cystectomy. Thus, a total of 37 of 91 patients (40%) required cystectomy. The 4-year cumulative risk of invasive local failure (which includes induction failures) was 43% (95% CI, 33% to 53%). The 4-year actuarial risk of distant metastasis was 22% (95% CI, 13% to 31%). The 4-year actuarial survival rate of the entire group was 62% (95% CI, 52% to 72%). The 4-year actuarial rate of survival with bladder intact was 44% (95% CI, 34% to 54%). CONCLUSION Initial results of this combined chemoradiotherapy program show that bladder preservation can be achieved in the majority of patients, and that overall survival is similar to that reported with aggressive surgical approaches. Long-term survival and quality-of-life assessments require longer follow-up study." @default.
• W1786366031 created "2016-06-24" @default.
• W1786366031 creator A5012866369 @default.
• W1786366031 creator A5031665183 @default.
• W1786366031 creator A5034997866 @default.
• W1786366031 creator A5057439948 @default.
• W1786366031 creator A5068270443 @default.
• W1786366031 creator A5081885325 @default.
• W1786366031 creator A5085643126 @default.
• W1786366031 creator A5090983067 @default.
• W1786366031 date "1996-01-01" @default.
• W1786366031 modified "2023-09-27" @default.
• W1786366031 title "Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802." @default.
• W1786366031 cites W117818932 @default.
• W1786366031 cites W1774531900 @default.
• W1786366031 cites W1893740135 @default.
• W1786366031 cites W1939723756 @default.
• W1786366031 cites W1952252771 @default.
• W1786366031 cites W1974590513 @default.
• W1786366031 cites W1979300931 @default.
• W1786366031 cites W2026249603 @default.
• W1786366031 cites W2028522982 @default.
• W1786366031 cites W2034305770 @default.
• W1786366031 cites W2040305767 @default.
• W1786366031 cites W2043945205 @default.
• W1786366031 cites W2047676112 @default.
• W1786366031 cites W2049695002 @default.
• W1786366031 cites W2072167013 @default.
• W1786366031 cites W2089487696 @default.
• W1786366031 cites W2125713359 @default.
• W1786366031 cites W2137654361 @default.
• W1786366031 cites W2143656505 @default.
• W1786366031 cites W2159860478 @default.
• W1786366031 cites W2163740969 @default.
• W1786366031 cites W2268861790 @default.
• W1786366031 cites W2313608588 @default.
• W1786366031 cites W2318032547 @default.
• W1786366031 cites W2406945847 @default.
• W1786366031 cites W2410167743 @default.
• W1786366031 cites W2437809893 @default.
• W1786366031 doi "https://doi.org/10.1200/jco.1996.14.1.119" @default.
• W1786366031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8558186" @default.
• W1786366031 hasPublicationYear "1996" @default.
• W1786366031 type Work @default.
• W1786366031 sameAs 1786366031 @default.
• W1786366031 citedByCount "250" @default.
• W1786366031 countsByYear W17863660312012 @default.
• W1786366031 countsByYear W17863660312013 @default.
• W1786366031 countsByYear W17863660312014 @default.
• W1786366031 countsByYear W17863660312015 @default.
• W1786366031 countsByYear W17863660312016 @default.
• W1786366031 countsByYear W17863660312017 @default.
• W1786366031 countsByYear W17863660312018 @default.
• W1786366031 countsByYear W17863660312019 @default.
• W1786366031 countsByYear W17863660312020 @default.
• W1786366031 countsByYear W17863660312021 @default.
• W1786366031 countsByYear W17863660312022 @default.
• W1786366031 countsByYear W17863660312023 @default.
• W1786366031 crossrefType "journal-article" @default.
• W1786366031 hasAuthorship W1786366031A5012866369 @default.
• W1786366031 hasAuthorship W1786366031A5031665183 @default.
• W1786366031 hasAuthorship W1786366031A5034997866 @default.
• W1786366031 hasAuthorship W1786366031A5057439948 @default.
• W1786366031 hasAuthorship W1786366031A5068270443 @default.
• W1786366031 hasAuthorship W1786366031A5081885325 @default.
• W1786366031 hasAuthorship W1786366031A5085643126 @default.
• W1786366031 hasAuthorship W1786366031A5090983067 @default.
• W1786366031 hasConcept C121608353 @default.
• W1786366031 hasConcept C126322002 @default.
• W1786366031 hasConcept C126894567 @default.
• W1786366031 hasConcept C141071460 @default.
• W1786366031 hasConcept C143998085 @default.
• W1786366031 hasConcept C2775910329 @default.
• W1786366031 hasConcept C2776694085 @default.
• W1786366031 hasConcept C2777132456 @default.
• W1786366031 hasConcept C2778239845 @default.
• W1786366031 hasConcept C2778424827 @default.
• W1786366031 hasConcept C2780352672 @default.
• W1786366031 hasConcept C2781413609 @default.
• W1786366031 hasConcept C509974204 @default.
• W1786366031 hasConcept C71924100 @default.
• W1786366031 hasConceptScore W1786366031C121608353 @default.
• W1786366031 hasConceptScore W1786366031C126322002 @default.
• W1786366031 hasConceptScore W1786366031C126894567 @default.
• W1786366031 hasConceptScore W1786366031C141071460 @default.
• W1786366031 hasConceptScore W1786366031C143998085 @default.
• W1786366031 hasConceptScore W1786366031C2775910329 @default.
• W1786366031 hasConceptScore W1786366031C2776694085 @default.
• W1786366031 hasConceptScore W1786366031C2777132456 @default.
• W1786366031 hasConceptScore W1786366031C2778239845 @default.
• W1786366031 hasConceptScore W1786366031C2778424827 @default.
• W1786366031 hasConceptScore W1786366031C2780352672 @default.
• W1786366031 hasConceptScore W1786366031C2781413609 @default.
• W1786366031 hasConceptScore W1786366031C509974204 @default.
• W1786366031 hasConceptScore W1786366031C71924100 @default.
• W1786366031 hasIssue "1" @default.
• W1786366031 hasLocation W17863660311 @default.
• W1786366031 hasLocation W17863660312 @default.

• next